Elizabeth Griffiths, MD, associate professor of oncology, department of medicine, Roswell Park Comprehensive Cancer Center, discusses the prevalence of neutropenia in patients with acute myeloid leukemia and patient/clinical characteristics that can predict which patients will become neutropenic.
Elizabeth Griffiths, MD, associate professor of oncology, department of medicine, Roswell Park Comprehensive Cancer Center, discusses the prevalence of neutropenia in patients with acute myeloid leukemia (AML) and patient/clinical characteristics that can predict which patients will become neutropenic.
Transcript
How prevalent is neutropenia in patients with AML, and are there any patient/clinical characteristics that can help predict which patients will become neutropenic?
Any patient who receives an intensive induction strategy is likely to have neutropenia. The neutropenia when you give an intensive induction strategy usually is relatively self-limited on the order of 2 weeks or 3 weeks. The duration of neutropenia can be more prolonged in older patients and people who have secondary leukemia who previously received chemotherapy, or in people who are frail or unfit.
Neutropenia is strongly associated with the risk of developing infections, especially invasive fungal infections. So, one of the things we do to mitigate the risks associated with neutropenia is we use a variety of prophylactic antibiotics, which are part of the big changes and the big improvements we’ve had in the standard of care for patients with AML.
When we think about alternative induction strategies; things like the hypomethylating agents alone or in combination with drugs targeting BCL2, like venetoclax. The periods of neutropenia that you get with those agents are markedly more prolonged and can be persistent for several months. This is also true for patients receiving IDH [isocitrate dehydrogenase] inhibitor therapies, where what you see is differentiation rather than cytotoxicity. And sometimes the neutropenia can last a long time.
FLT3 therapies are also associated with these periods where the patients have prolonged cytopenias but are alive. So, because we have these long periods of neutropenia, and these patients receiving alternative induction strategies or alternative therapies for relapsed and refractory disease, we have a lot of neutropenia in our patients.
These prolonged periods of neutropenia are associated with an increased risk of invasive fungal infection, and so for that reason, I think the use of prophylactic therapy for invasive fungal infection is really, really important. I think it’s also really important to recognize that the combination of venetoclax, or BCLT2 inhibitor, with effective second or third generation antifungals results in substantial changes in the bioavailability of the venetoclax, particularly.
And so, it’s important to consider dose reduction of the venetoclax in patients in whom your using a mold-active antifungal. So, that’s been described, particularly the strategy for dose reduction with posaconazole given with venetoclax has been described. I think with the other agents we have a little bit less data, but it’s certainly a substantial issue.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More